Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types.
Melatonin is released in mammals during the dark phase of the circadian cycle, and its production declines with age in animals and humans. Since supplemental administration of melatonin may be beneficial in delaying age-related degenerative conditions, it is necessary to study its effect on neuronal differentiation and the processing of key neuronal proteins, such as beta-amyloid precursor protein (beta APP) and synaptophysin. One of the important pathological hallmarks of Alzheimer's disease (AD) is the cerebrovascular deposition of amyloid plaques. The amyloid in senile plaques is mainly composed of the amyloid beta-peptide (A beta) of 39-43 amino acids derived from a larger beta APP. The proteolytic cleavage by 'alpha-secretase' generate soluble derivatives of beta APP (sAPP), lacking the cytoplasmic tail, transmembrane domain, and a small portion of the extracellular domain. Here levels of sAPP and beta APP were analyzed in cell lines of different origins by Western immunoblot of samples from conditioned media and cell lysates, respectively. Normal levels of secretion of sAPP into conditioned media were severely inhibited by treating different cell lines with a high dose of melatonin. In PC12 cells, levels of the fully matured beta APP forms of the post-Golgi compartment were more drastically decreased than the unglycosylated beta APP of the endoplasmic-reticulum (ER) forms. In other cell types, the unglycosylated ER-bound beta APP derivatives are predominant forms that were marginally affected by melatonin treatment. When the treatment of cells with melatonin was withdrawn, the normal level of secretion of sAPP was restored. Melatonin reduces the secretion of soluble A beta. Melatonin also inhibits the secretion of synaptophysin in PC12 cells. Taken together, these data suggest that melatonin probably affects the secretion of sAPP in the conditioned medium by interfering with its full maturation, and melatonin also affects the presysnaptic terminal marker.
Lahiri
D K
DK
Department of Psychiatry and Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis 46202, USA. dlahiri@iupui.edu
D016564:Amyloid beta-Protein Precursor / Q000378:metabolism*; D000818:Animals; D002217:Carbachol / Q000494:pharmacology; D002460:Cell Line; D017077:Culture Media, Conditioned; D004305:Dose-Response Relationship, Drug; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D006031:Glycosylation; D006801:Humans; D007668:Kidney / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D008550:Melatonin / Q000494:pharmacology*; D008970:Molecular Weight; D009447:Neuroblastoma / Q000378:metabolism; D009457:Neuroglia / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D010446:Peptide Fragments / Q000378:metabolism*; D011480:Protease Inhibitors / Q000494:pharmacology; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D012995:Solubility; D016708:Synaptophysin / Q000378:metabolism; D014407:Tumor Cells, Cultured
D016564:Amyloid beta-Protein Precursor; D017077:Culture Media, Conditioned; D010446:Peptide Fragments; D011480:Protease Inhibitors; D016708:Synaptophysin; D002217:Carbachol; D008550:Melatonin